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Comparison of the malaria parasite and mammalian
protein prenyltransferases and their cellular substrates
is important for establishing this enzyme as a target for
developing antimalarial agents. Nineteen heptapeptides
differing only in their carboxyl-terminal amino acid
were tested as alternative substrates of partially puri-
fied Plasmodium falciparum protein farnesyltrans-
ferase. Only NRSCAIM and NRSCAIQ serve as sub-
strates, with NRSCAIM being the best. Peptidomimetics,
FTI-276 and GGTI-287, inhibit the transferase with IC50
values of 1 and 32 nM, respectively. Incubation of
P. falciparum-infected erythrocytes with [3H]farnesol
labels 50- and 22–28-kDa proteins, whereas [3H]gera-
nylgeraniol labels only 22–28-kDa proteins. The 50-kDa
protein is shown to be farnesylated, whereas the 22–28-
kDa proteins are geranylgeranylated, irrespective of the
labeling prenol. Protein labeling is inhibited more than
50% by either 5 M FTI-277 or GGTI-298. The same con-
centration of inhibitors also inhibits parasite growth
from the ring stage by 50%, decreases expression of pre-
nylated proteins as measured with prenyl-specific anti-
body, and inhibits parasite differentiation beyond the
trophozoite stage. Furthermore, differentiation specific
prenylation of P. falciparum proteins is demonstrated.
Protein labeling is detected predominantly during the
trophozoite to schizont and schizont to ring transitions.
These results demonstrate unique properties of protein
prenylation in P. falciparum: a limited specificity of the
farnesyltransferase for peptide substrates compared
with mammalian enzymes, the ability to use farnesol to
label both farnesyl and geranylgeranyl moieties on pro-
teins, differentiation specific protein prenylation, and
the ability of peptidomimetic prenyltransferase inhibi-
tors to block parasite differentiation.
Malaria continues to be a major disease in tropical areas of
the world. Parasite resistance to current drugs used in the
treatment of malaria has lead investigators to seek out new
drug targets. Among those targets are proteins and enzymes,
which are necessary for cellular division and differentiation.
Such targets include the protein prenyltransferases, which are
necessary for the post-translational modification of proteins
involved in the signal transduction pathways and in regulation
of DNA replication and cell cycling (1–3). These enzymes are
currently a major focus of efforts to design drugs that inhibit
unregulated cell growth in cancer (4, 5). Several candidate
compounds show great promise as antitumor drugs and are
currently being tested in clinical trials. The potential for the
application of such drugs to inhibit malarial parasite division
and differentiation motivates one to examine the properties of
the protozoan enzyme with the goal of identifying unique fea-
tures of this enzyme that would make it a target for the devel-
opment of parasite-specific drugs.
A variety of proteins including small G-proteins, such as Ras,
Rac, Rap, Rho, Rab (6), heterotrimeric G protein  subunits (7),
nuclear lamins (8), protein kinases (9), and protein-tyrosine
phosphatases, PTPCAAX (10), are post-translationally preny-
lated near the carboxyl terminus with farnesyl (C15) or gera-
nylgeranyl (C20) groups. Some of these, notably Ras, are farne-
sylated and play an important role in the regulation of DNA
replication and cell cycling (1–3). The C20-modified proteins
have a variety of cellular functions including intracellular ve-
sicular trafficking. The attachment of the farnesyl or gera-
nylgeranyl groups to these proteins generally promotes mem-
brane association. Inhibition of farnesylation of oncogenic Ras,
for example, decreases association of Ras with membrane and
blocks cell transformation (11, 12).
The protein prenyltransferases catalyzing these lipid addi-
tion reactions show specificity for the carboxyl-terminal amino
acid sequence to be modified. Mammalian protein farnesyl-
transferase (PFT)1 farnesylates the cysteine residue in carbox-
yl-terminal cysteine-aaaliphatic-aaaliphatic-aax (CAAX) se-
quences, where aax is methionine, glutamine, serine,
threonine, or cysteine (13–16). Protein geranylgeranyl trans-
ferase-I (PGGT-I) shows specificity for cysteine-aaaliphatic-
aaaliphatic-leucine sequences (13, 17–20). Both PFT and PGGT-I
can recognize synthetic short peptides as substrates and inhib-
itors (13, 18, 19). Protein geranylgeranyl transferase-II (Rab-
PGGT), in contrast, modifies proteins with a cysteine-cysteine,
cysteine-cysteine-aax-aax, or cysteine-aax-cysteine carboxyl-
terminal sequences but cannot prenylate or be inhibited by
synthetic short peptides (13, 21).
Although knowledge of the protein prenyltransferases in
lower eukaryotes other than yeast is very limited, protein pre-
nylation has been demonstrated in the parasites Giardia lam-
blia (22), Schistosoma mansoni (23), Trypanosoma brucei (24,
25), Trypanosoma cruzi (26), Leishmania mexicanan (26), and
Toxoplasma gondii (27). Yokoyama et al. (25) reported PFT and
PGGT-I activities in T. brucei, cloned the T. brucei PFT, and
* This work was supported by National Institutes of Health Grant
R01 AI43679 (to C. M. A.). The costs of publication of this article were
defrayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed. Tel.: 352-392-3366;
Fax: 352-392-2953; E-mail: callen@biochem.med.ufl.edu.
1 The abbreviations used are: PFT, protein farnesyltransferase; Pf-
PFT, Plasmodium falciparum protein farnesyltransferase; PGGT-I,
protein geranylgeranyl transferase-I; FTI, farnesyltransferase inhibi-
tor; GGTI, geranylgeranyl transferase inhibitor; SPA, scintillation
proximation assay.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 277, No. 44, Issue of November 1, pp. 42066–42073, 2002
© 2002 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org42066
 at U
CF H
ealth Sciences Library on Septem
ber 24, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
described its substrate specificity (28, 29). Recently Buckner et
al. (30) reported the cloning and substrate specificity of T. cruzi
and Leishmania major PFT. We described PFT and PGGT-I
activity in P. falciparum, the protozoan malaria parasite, and
hence presented the first indication that protein prenylation is
functional in this parasite (31). Our description of the strong
inhibition of P. falciparum PFT (PfPFT) by peptidomimetics
illustrated the potential of targeting these enzymes in devel-
oping drug therapy for malaria. We describe here the prenyla-
tion of P. falciparum proteins in culture from exogenously
supplied prenols and inhibition of this process with peptidomi-
metics. Ohkanda et al. (32) have recently demonstrated the
potency of a variety of other peptidomimetics as inhibitors of
P. falciparum growth and PfPFT activity. Moura et al. (33)
have also shown that the monoterpene, limonene, inhibits par-
asite development and prenylation of P. falciparum proteins.
These findings clearly present PFT as a target for the develop-
ment of antimalarial drugs. The results presented here provide
the first description of PfPFT substrate specificity, further
focus the target for inhibitors on competitors of peptide bind-
ing, and identify specific P. falciparum proteins for further
characterization as natural substrates for prenylation.
EXPERIMENTAL PROCEDURES
Materials—[3H]Farnesol and [3H]geranylgeraniol were purchased
from American Radiolabeled Chemicals. The SPA PFT kit was pur-
chased from Amersham Biosciences. Inhibitors of protein prenyltrans-
ferases were purchased from Calbiochem, except FTase IV, D-trypto-
phan-D-methionine-D-p-chlorophenylalanine-L--carboxyglutamic acid
(Bachem). All other substrates were available from other commercial
suppliers. Nineteen heptapeptides were synthesized by solid phase
methodology using Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry,
purified by high performance liquid chromatography, and characterized
by mass spectroscopy at the Protein Chemistry Core Facility, Univer-
sity of Florida Biotechnology Program. Twelve of the peptides were
synthesized in two groups with a mixture of COOH-terminal amino
acids, NRSCAI{Ile,Glu,Arg,Gly,Asn,His} and NRSCAI{Tyr,Trp,Val,
Asp,Lys,Cys}. Individual peptides from each of these groups were sep-
arated by high performance liquid chromatography. Because NRSCAIN
and NRSCAIH were not separated by high performance liquid chroma-
tography they were tested as a mixture. All stock solutions of peptides
were stored in 50 mM HEPES, pH 7.7, 5 mM dithiothreitol, 5 mM MgCl2,
and 20% glycerol.
Growth and Isolation of P. falciparum—P. falciparum 3D7 was
grown in vitro in a modified erythrocyte culture as previously described
(31, 34). The parasite pellet was isolated from infected erythrocytes by
treatment with 0.1% (w/v) saponin for 5 min followed by two washes
with phosphate-buffered saline, pH 7.2, at 1,800  g for 7 min. When
needed, cultures were synchronized with 5% sorbitol (35). Typically
parasites were harvested, post-synchronization, at 6 h for rings, 20 h for
trophozoites and 32 h for schizonts. The yield was about 4–5  107
parasites ml1 of culture. The growth of parasites was monitored by
light microscopy of Leukostat (Fisher)-stained thin smears. Pellets of
parasites were stored at 80 °C. They were stable in this form for at
least 6 months.
Partial Purification of Protein Farnesyltransferase—Conceptual
translation of two open reading frames, chr12_1.glm_484 and
chr11_1.glm_536, obtained from the malaria genome data base (www.
plasmodb.org) yields protein sequences that undoubtedly describe the 
and  subunits, respectively, of PfPFT. However, multiple attempts to
express PfPFT in Escherichia coli as a translationally coupled het-
erodimer have not been successful to date. In the absence of recombi-
nant enzyme, native PfPFT, which was partially purified by ammonium
sulfate fractionation or Mono Q chromatography, has been used for in
vitro assays. Parasite pellets from 1 liter of cultures (100 plates at
10–20% parasitemia, predominantly trophozoites) were homogenized
at 4 °C and the cell suspension was sonicated to disrupt the cells as
previously described (31). The lysate was centrifuged at 100,000  g
with a 50.1 Ti rotor for 1 h at 4 °C and the protein precipitated between
0 and 50% saturated ammonium sulfate was collected. The ammonium
sulfate precipitate was suspended in and dialyzed against 50 mM Tris-
HCl, pH 7.5, 1 mM dithiothreitol, 20 M ZnCl2, 20 mM NaCl at 4 °C. The
ammonium sulfate fraction was partially purified by Mono Q chroma-
tography by modifications of previously described methods at 4 °C (14,
31). Peak fractions were pooled, concentrated by ultrafiltration, and
stored at 80 °C.
Enzyme Assays and Inhibitor Studies—Assays for PfPFT were car-
ried out with the scintillation proximation assay (SPA) according to the
manufacturers (Amersham Biosciences) recommendations using 0.12
M [3H]farnesyl diphosphate and 0.1 M biotinylated lamin B peptide
(biotinyl-YRASNRSCAIM) as substrates, unless otherwise stated. For
studies with peptidomimetics with limited aqueous solubility (all except
FTase II), each was dissolved in dimethyl sulfoxide. Aliquots (2–4 l) of
these solutions were added to 100-l SPA assay mixtures. Controls for
inhibition of PFT activity in the presence of dimethyl sulfoxide were
included in each experiment. Control values for reaction mixtures con-
taining no biotinylated peptide were subtracted from values obtained
from complete incubations before calculations of percent inhibition. The
effectiveness of each inhibitor is reported as an IC50 value, the concen-
tration of inhibitor that reduces the activity of PfPFT to 50% of its
uninhibited activity under the conditions tested.
Enzyme assays using nonbiotinylated peptides as substrates were
incubated under the same conditions as described for the SPA, except
that different nonbiotinylated heptapeptides (2 M) were substituted
for the biotinylated lamin B peptide. The amount of prenylated product
was quantitated after purification on 1-ml SPE anion exchange chro-
matography columns (J. T. Baker Inc.) (28). The first two eluted frac-
tions were pooled and subjected to TLC on silica G sheets in 1-propanol,
NH4OH, water (6:3:1, v/v/v). The positions of migration of the preny-
lated peptides were determined by cutting each lane into 1-cm sections
and analyzing for radioactivity. Prenylated peptides (1000–2000 cpm)
migrated with RF values of 0.69, which is consistent with previously
reported RF values (0.67–0.74) for this system (37). [
3H]Farnesol, the
product of phosphatase action on [3H]farnesyl diphosphate, is a com-
mon by-product of the reaction mixtures and chromatographs, as is
unlabeled farnesol with an RF of 0.87.
Nineteen nonbiotinylated heptapeptides at 10 M concentration were
also tested as alternative substrates or inhibitors by an indirect method
using the SPA and 2.5 g of Mono Q-purified PfPFT. Enzyme activity
without added heptapeptide (control) was assigned the value of 100%.
The activity of PfPFT in the presence of each heptapeptide was assessed
relative to the 100% control. A decrease (inhibition) in percentage of
control activity indicates the peptide functions as an alternative
substrate.
Radiolabeling of P. falciparum Prenylated Proteins—Asynchronous
cultures (1 ml) of P. falciparum were labeled with 10 Ci of [3H]farnesol
or [3H]geranylgeraniol for 24 h in the presence or absence of different
peptidomimetics. Inhibitors (5 l in dimethyl sulfoxide) were added at
the same time as the labeling agent. Labeled parasites were released
from infected erythrocytes by saponin treatment as previously de-
scribed (31). The parasite sample was washed several times with phos-
phate-buffered saline and lysed by addition of 24 l of M-Per lysis
reagent (Pierce). Lysed parasite extracts were resolved by SDS-PAGE
on 12% gels according to the method of Laemmli (38). The gel was
subjected to fluorography following treatment with Amplify (Amersham
Biosciences). Typically gels were exposed to x-ray films for 7–28 days at
80 °C. The effect of FTI-277 and GGTI-298 on protein synthesis was
tested by labeling cells with 35S-Pro Mix (Amersham Biosciences) in
RPMI 1640 medium deficient in methionine and cysteine for 24 h in the
presence of different inhibitors. Cell extracts were prepared, resolved
on SDS-PAGE, and subjected to autoradiography. No inhibition of pro-
tein synthesis was observed at concentrations of inhibitors that signif-
icantly inhibited prenylation. Synchronized parasite cultures (1 ml at
6% parasitemia) were labeled as described above with either 5 Ci of
[3H]farnesol or [3H]geranylgeraniol for 16 h starting at ring, trophozo-
ite, and schizont stages.
Determination of Mode of Protein Prenylation—The nature of the
radiolabeled prenyl moiety attached to P. falciparum proteins was
determined following metabolic labeling with [3H]farnesol and
[3H]geranylgeraniol. Gel segments corresponding to labeled proteins
were cut out, and treated with methyl iodide and base according the the
method of Casey et al. (39) as modified by Dugan and Allen (40). The
free prenols released by this treatment were separated by reverse phase
TLC on KC8 plates (Whatman) in acetonitrile, H2O (9:1, v/v) and iden-
tified by comparison to the mobilities of standards of farnesol and
geranylgeraniol.
Two-dimensional Analysis of Stage-specific Labeled Proteins—Pro-
teins isolated from cultures (1 ml) labeled with 10 Ci of [3H]farnesol or
[3H]geranylgeraniol were analyzed by two-dimensional electrophoresis
according to the method of O’Farrell (41) by Kendricks Labs, Inc.
(Madison, WI). Isoelectric focusing was carried out in glass tubes of 2.0
mm inner diameter, using 2.0% pH 4–8 ampholines (BDH, Gallard
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Schlesinger, Long Island, NY) for 9600 volt h. Following equilibration
for 10 min in 10% glycerol, 50 mM dithiothreitol, 2.3% SDS, and 62.5 mM
Tris, pH 6.8, the tube gel was sealed to the top of a stacking gel of a 10%
acrylamide slab gel (0.75 mm thick). SDS-gel electrophoresis was car-
ried out for 4 h at 12.5 mA/gel. The gels were treated with EN3HANCE
(PerkinElmer Life Sciences) for 1 h, rehydrated in water for 30 min, and
dried onto filter paper. Fluorography was carried out using Kodak
X-Omat AR film with exposures at 70 °C for 28 days.
Effect of Prenyltransferase Inhibitors on P. falciparum Maturation—
Various concentrations of inhibitors (in dimethyl sulfoxide) were added
to synchronized P. falciparum 3D7 culture at the ring stage (6 h post-
synchronization). The inhibition of growth was measured in terms of
inhibition of incorporation of [3H]hypoxanthine (0.2 Ci/well) into nu-
cleic acids. Cells were harvested in a cell harvester (TomTec MachIIM
Harvester 96) and counted for radioactivity. Images of stained thin
smears of inhibitor-treated cells were captured with a Zeiss Axioplan2
microscope equipped with a Hamamatsu color chilled 3CCD camera.
Indirect Immunofluorescence Microscopy—Synchronized parasite-in-
fected erythrocytes were washed twice with RPMI 1640 and at a cell
density of 1  107 cells/ml were allowed to adhere to poly-L-lysine-
coated coverslips at 37 °C for 30 min. The slides were washed four times
with phosphate-buffered saline and fixed in 4% paraformaldehyde (10
min at room temperature). Following four washes with phosphate-
buffered saline, the cells were permeabilized and blocked with a solu-
tion containing 0.05% saponin, 5% bovine serum albumin for 20 min at
room temperature. The cells were probed with an affinity purified
rabbit anti-farnesyl polyclonal antibody (Calbiochem) at a dilution of
1:50 and affinity purified Cy2-labeled goat anti-rabbit IgG (Jackson
Immunoresearch Laboratories) at a dilution of 1:200 in phosphate-
buffered saline containing 5% bovine serum albumin, respectively, for
90 min followed by three washes with phosphate-buffered saline. Nu-
clear staining was done with 1 M 4,6-diamidino-2-phenylindole for 5
min. The coverslips were mounted with gel/mount (Biomeda) on slides.
The slides were viewed on a DeltaVision restoration microscope system
(Applied Precision) equipped with a Nikon TE200 microscope and a
Photometrix cooled CCD camera. DeltaVision software (SoftWoRx) was
used for image deconvolusion.
RESULTS
In Vitro Inhibition of PfPFT with Peptidomimetics—Our ear-
lier studies showed that PfPFT was poorly inhibited by the
farnesyl diphosphate analogues FPT inhibitor-I and -II,
whereas the peptidomimetic PFT inhibitor, L-745631, was an
effective inhibitor with an IC50 of 3–4 nM (31). Several addi-
tional peptidomimetics (Table I) were tested here with Mono
Q-purified PfPFT. PFT inhibitor, FTI-276, and geranylgeranyl
transferase inhibitors, GGTI-287 and GGTI-297, each inhibit
at concentrations comparable with those reported for the mam-
malian PFTs (Table II). FTI-276 shows the best inhibition and
is slightly more inhibitory than L-745631. Other commercially
available peptidomimetic PFT inhibitors, FTase-I, FTase-II,
and FTase-IV are relatively ineffective inhibitors of PfPFT
(IC50 of 1.7–6.3 M).
Peptide Substrate Specificity of PfPFT—Seven heptapep-
tides, NRSCAIX, with carboxyl-terminal residues of methio-
nine, alanine, serine, threonine, phenylalanine, glutamine, or
leucine were tested directly as substrates of PfPFT. Each un-
biotinylated peptide was incubated with [3H]farnesyl diphos-
phate and ammonium sulfate-fractionated enzymes as de-
scribed under “Experimental Procedures.” Prenylated peptides
were then purified by SPE anion exchange chromatography
and TLC. Among the peptides tested, NRSCAIM and NR-
SCAIQ were the best substrates. Quantitation of the preny-
lated peptides showed that the reactivities of the different
NRSCAIX peptides, relative to NRSCAIM taken as 100%, were
40, 7.5, 3.0, 3.0, 1.5, and 0%, respectively, when the carboxyl
termini were of glutamine, leucine, serine, threonine, alanine,
and phenylalanine.
A convenient and more rapid method of assessing the peptide
specificity of the enzyme is to test unbiotinylated peptides as
alternative substrates or inhibitors of prenyltransferase activ-
ity as measured by the SPA assay. Binding of unbiotinylated
peptide to the enzyme active site will decrease binding of the
biotinylated SPA peptide substrate and hence decrease the
amount of biotinylated [3H]farnesyl peptide formed and
trapped with SPA streptavidin beads. Nineteen CAAX contain-
ing heptapeptides (NRSCAIX), with sequences corresponding
to lamin B, but having different carboxyl termini, were tested
as alternative substrates of the Mono Q-purified PfPFT using
the SPA assay. Among the peptides tested only NRSCAIM and
NRSCAIQ functioned as alternative substrates. The effect of
varying concentrations of NRSCAIM and NRSCAIQ on enzyme
activity is illustrated in Fig. 1. Respective IC50 values of 1 and
21 M were obtained.
Stage-dependent Prenylation of Parasite Proteins—Develop-
ment stage-specific prenylation of proteins during intraeryth-
TABLE I
Peptidomimetic prenyltransferase inhibitors
TABLE II
IC50 values for peptidomimetic inhibitors of PfPFT
Peptidomimetics FTI and GGTI were tested as inhibitors of Mono
Q-purified PfPFT. FTase inhibitors were tested with ammonium sul-
fate-purified enzyme. The scintillation proximation assay was used in
each case. The values reported for the human PFT are literature values.
Inhibitor
IC50
P. falciparum Human
nM
FTI-276 0.9 0.5a
GGTI-287 32 25b
GGTI-297 190 200a
FTase inhibitor II 1,700 50c
FTase inhibitor IV 5,000 2d
FTase inhibitor I 6,300 21e
a Ref. 42.
b Ref. 43.
c Ref. 44.
d Ref. 45.
e Ref. 46.
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rocytic development of the parasite was analyzed next. Syn-
chronized parasites were labeled with [3H]farnesol and
[3H]geranylgeraniol for 16 h starting at ring, trophozoite, and
schizont stages. As seen from Fig. 2A, labeling with [3H]farne-
sol results in detection of 50 kDa as well as 22–28-kDa preny-
lated proteins, predominantly during the trophozoite to schi-
zont transition (lane 2). Although significantly less, prenylated
proteins of these sizes are also detected during schizont to ring
transition (lane 3). Very little prenylation of proteins is de-
tected during ring to early trophozoite transition (lane 1). In-
cubation with [3H]geranylgeraniol resulted in labeled proteins
in the 22–28-kDa range in all stages of intraerythrocytic
growth (Fig. 2B, lane 1-3) reaching a peak during maturation of
trophozoites into schizonts. At times, trace labeling of a 50-kDa
protein is observed. It is to be noted that we have not detected
protein prenylation in uninfected erythrocytes (data not
shown). Furthermore, the appearance of little or no detectable
protein prenylation in the ring stage (Fig. 2, lanes A1 and B1)
also suggests no contribution from prenylation of erythrocytic
proteins.
Two-dimensional Separation of Proteins Labeled with Prenyl
Groups during Malaria Parasite Intraerythrocytic Differentia-
tion—Proteins radiolabeled with [3H]farnesol or with [3H]gera-
nylgeraniol during P. falciparum differentiation in erythro-
cytes were also separated by two-dimensional electrophoresis.
Multiple labeled proteins are observed in both the 50- and
22–28-kDa range when using [3H]farnesol (Fig. 3). Proteins in
the 50,000 range are found predominately in the trophozoite
stage (Fig. 3B, also see Fig. 2A, lane 2) and they appear to be of
the same molecular weight but of different charge. Multiple
proteins are found in the 22–28-kDa range of cells in both the
trophozoite (Fig. 3B) and schizont (Fig. 3C) stages. Several
proteins appear to be common to the two stages judging from
their position of migration, however, there is differential label-
ing with some and at least one protein is labeled specifically at
the schizont stage. With [3H]geranylgeraniol labeling, the 22–
28-kDa protein population appeared with charge heterogeneity
(data not shown).
Mode of Prenylation of P. falciparum Proteins—The nature
of the prenyl moiety attached to P. falciparum proteins was
determined following metabolic labeling with [3H]prenols. Pro-
teins were separated by SDS-PAGE and gel segments corre-
sponding to labeled prenylated proteins were subjected to a
methyl iodide treatment, which releases the prenyl moieties as
free prenols. Reverse phase TLC analysis of prenols released
from the 50-kDa protein, which was radiolabeled in cultures
containing [3H]farnesol, shows only farnesol (Fig. 4). In con-
trast, the prenol released from each of the three bands in the
22–28-kDa range is geranylgeraniol. Similar analysis of the
22–28-kDa proteins from cultures incubated with [3H]gera-
nylgeraniol showed that these proteins were geranylgerany-
lated (data not shown). Analysis of the prenols associated with
proteins labeled with [3H]prenols in the stage dependent study
(Fig. 2A) shows the same prenylation pattern. The 50-kDa
protein is farnesylated with [3H]farnesol labeling, whereas the
22–28-kDa proteins are geranylgeranylated with either
[3H]farnesol or [3H]geranylgeraniol labeling.
Inhibition of P. falciparum Intraerythrocytic Maturation—
The effects of peptidomimetic prenyltransferase inhibitors
were tested on the growth of P. falciparum in the erythrocytic
culture. Both FTI-277 and GGTI-298, the methyl esters of
FTI-276 and GGTI-297, respectively, exhibit an IC50 of 5 M
(data not shown). The FTI-277-treated culture forms a vacuole-
like structure (Fig. 5, panel 3). Similar vacuoles are not ob-
served in control cells (Fig. 5, panel 2). Furthermore, the in-
hibitor-treated cells do not mature beyond the trophozoite
stage and the few parasites that escape inhibition at the IC50
inhibitor concentration mature normally but are arrested at
the trophozoite stage in the next developmental cycle (data not
shown).
Changes in the Intracellular Localization of Prenylated Pro-
teins following Treatment with Peptidomimetics—To analyze
the localization of prenylated proteins in P. falciparum, a com-
mercially available rabbit farnesyl polyclonal antibody was
used in an indirect immunofluorescence experiment. This an-
tibody was generated using farnesyl cysteine conjugated to
keyhole limpet hemocyanin and cross-reacts also with gera-
nylgeranylated proteins. Prenylated proteins exhibit distinct
foci of localization and are detected in all stages of intraeryth-
rocytic maturation (Fig. 6). Inhibitor treatment was initiated in
the ring stage (0 h) and in 24 h the cells matured to late
trophozoites. At 36 h the cells are in the schizont/segmentor
stage as evident from multinucleated cells (Fig. 6, panel I).
Upon treatment with 5 M FTI-277 or GGTI-298 (Fig. 6, panels
II and IV) there is a significant reduction of intracellular pre-
nylated protein. The fluorescence-labeled prenylated proteins
are almost undetectable in the presence of 10 M peptidomi-
FIG. 1. Concentration dependence of NRSCAIM and NRSCAIQ
as alternative substrates of PfPFT. The ability of different concen-
trations of peptides NRSCAIM () and NRSCAIQ (f) to decrease the
apparent activity of ammonium sulfate-purified PfPFT was measured
using the SPA. PfPFT activity without added heptapeptide was as-
signed the value of 100% activity. The relative PfPFT activities and
standard errors at various concentrations of heptapeptide are plotted.
FIG. 2. Labeling of synchronized parasite cultures. Synchro-
nized parasite cultures were labeled with [3H]farnesol (A) or [3H]gera-
nylgeraniol (B) for 16 h starting at ring (1), trophozoite (2), and schizont
(3) stages as described under “Experimental Procedures.” Radiolabeled
parasite proteins were isolated, resolved by SDS-PAGE, and detected
by fluorography.
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metics and the maturation of cells is severely affected (Fig. 6,
panels III and V). The effect of peptidomimetics on the distri-
bution of prenylated proteins also provides evidence for the
specificity of the antibody. There was no fluorescence-labeled
prenylated proteins in uninfected erythrocytes.
Inhibition of in Vivo Radiolabeling of P. falciparum Preny-
lated Proteins with Peptidomimetics—To further test the effect
of prenyltransferase inhibitors on protein prenylation in the
malaria parasite, synchronous cultures of P. falciparum-in-
fected erythrocytes were labeled with [3H]farnesol or [3H]gera-
nylgeraniol in the presence or absence of different concentra-
tions of the FTI-277 or GGTI-298. Labeling of 22–28- and
50-kDa proteins, independent of the source of labeled prenol, is
inhibited by more than 50% by 5 M peptidomimetic, FTI-277
or GGTI-298 (Fig. 7, A and B). At these inhibitor concentra-
tions, no inhibition of protein synthesis was observed as evi-
dent from [35S]methionine incorporation into proteins indicat-
ing specific inhibition of protein prenylation without affecting
protein synthesis (data not shown).
DISCUSSION
Despite the fact that P. falciparum do not biosynthesize
cholesterol (47, 48), isoprenoid metabolism is critical for normal
parasite division and differentiation as evident from earlier
studies, which showed that PFT inhibitors (31) and mevastatin
(49), an inhibitor of -hydroxy--methylglutaryl-CoA reduc-
tase, affect the transition of parasites from the ring state to the
late trophozoite stage. The latter finding is intriguing as mev-
alonic acid-dependent synthesis of isopentenyl diphosphate is
yet to be established in the malaria parasite.
Our earlier attempts to radiolabel prenylated proteins in P.
falciparum with [3H]mevalonic acid were not successful. This
could be either attributed to the difficulty of transporting
enough mevalonic acid through both the cellular membranes of
the erythrocyte and the parasite to sufficiently label the iso-
prenoid pool, or to an alternative possibility that mevalonic
acid is not an intermediate in the synthetic pathway of prenyl
diphosphates used in protein prenylation, but the methyl
erythritol phosphate biosynthetic pathway is used (50, 51).
Recently, two key enzymes of this pathway, 1-deoxy-D-xylulose-
5-phosphate synthase and 1-deoxy-D-xylulose-5-phosphate re-
ductoisomerase, have been identified in Plasmodium (52). Con-
sequently, metabolic labeling of prenylated proteins with
radiolabeled prenols was used. Studies with mammalian cells
have shown that both [3H]farnesol and [3H]geranylgeraniol can
be used to label proteins (53, 54). The ability of these prenols to
serve as prenylation agents, based on our current state of
FIG. 3. Two-dimensional separation of proteins labeled with [3H]farnesol during erythrocytic stages of differentiation. Parasites
were labeled with [3H]farnesol during the ring (A), trophozoite (B), and schizont (C) stages of P. falciparum growth. Labeled proteins were isolated
and separated as described under “Experimental Procedures,” then were detected by fluorography. 14C-Labeled molecular weight markers (myosin,
200,000; phosphorylase b, 97,400; bovine serum albumin, 68,000; ovalbumin, 46,000; carbonic anhydrase, 30,000; and lysozyme, 14,300) appear at
the basic edge of the autoradiographs. The arrows represent the proteins, which are observed uniquely at that stage of differentiation.
FIG. 4. Mode of prenylation of P. falciparum proteins. Proteins
in asynchronous cultures of P. falciparum were radiolabeled with
[3H]farnesol. Gel segments corresponding to the indicated labeled pre-
nylated proteins were cut out. The prenyl moieties were released as free
prenols, separated by reverse phase TLC, and identified as described
under “Experimental Procedures.” The mobilities of farnesol (FOH) and
geranylgeraniol (GGOH) standards are shown.
FIG. 5. Effect of FTI-277 on the intraerythrocytic maturation
of P. falciparum. A synchronized parasite culture was treated with 5
M FTI-277 at the late ring stage. Panel 1, control culture containing
2.5% dimethyl sulfoxide at 0 h; panel 2, control culture after 24 h; panel
3, culture containing 5 M FTI-277 after 24 h.
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knowledge, requires the conversion of the prenols to their
diphosphate derivatives. Enzymes involved in these phospho-
rylations have been described and are reviewed (55).
Radiolabeled proteins were observed in asynchronous cul-
tures of P. falciparum-infected erythrocytes incubated with
either [3H]farnesol or [3H]geranylgeraniol. A 50-kDa protein
was shown to be metabolically labeled with [3H]farnesol but
not with [3H]geranylgeraniol. Analysis of the mode of prenyla-
tion showed farnesylation. Although proteins of 22–28 kDa
were labeled with either [3H]farnesol or [3H] geranylgeraniol,
analysis of their mode of prenylation showed almost exclusively
geranylgeranylation. It is apparent then that both [3H]farnesol
and [3H]geranylgeraniol are phosphorylated to their diphos-
phates and used for prenylation. Furthermore, some of the
[3H]farnesyl diphosphate must be elongated to [3H]gera-
nylgeranyl diphosphate to account for the appearance of
[3H]geranylgeranyl groups in 22–28-kDa proteins isolated from
cells labeled with [3H]farnesol.
Crick et al. (54) were able to demonstrate protein farnesyla-
tion in C6 glioma cells using [
3H]farnesol, but no protein gera-
nylgeranylation was seen. They raised the possibility of differ-
ential compartmentalization of the enzymes of isoprenoid
metabolism. Our ability to demonstrate protein geranylgera-
nylation using [3H]farnesol as a precursor, although different
from the results of Crick et al. (54), also suggests that compart-
mentalization of prenol metabolism and protein prenylation
may be a possibility. This is particularly evident when noting
that radiolabeling of the proteins in the 22–28-kDa range was
inhibited by the prenyltransferase inhibitors that are specific
for PFT and PGGT-I and not the Rab PGGT (42). Therefore,
although Rab proteins have been described in P. falciparum
(56), the labeled 22–28-kDa proteins are apparently not those
Rabs. The ability of PFT inhibitors to inhibit geranylgeranyla-
tion at low micromolar concentrations is also not readily ex-
plainable. We have reported the presence of PGGT-I in P.
falciparum (31), but our inability to isolate a stable PGGT-I
activity from P. falciparum extracts has prevented a determi-
nation of the sensitivity of PGGT-I to PFT and PGGT-I
inhibitors.
Prenylated proteins labeled with [3H]farnesol are observed
in both the 50- and 22–28-kDa ranges during the trophozoite to
schizont and schizont to ring stages of differentiation, whereas
few prenylated proteins are observed in the ring to trophozoite
stage. Our previous studies (31) demonstrated PFT and
PGGT-I activity in each of these stages, therefore this suggests
that the marked decrease in protein prenylation during the
ring to trophozoite transition is because of a decrease in the
production of suitable protein substrates for prenylation. It is
noteworthy that peptidomimetic L-745,631, a PFT inhibitor,
had no effect on the transition of schizont to early trophozoite
FIG. 6. Localization of prenylated proteins. Panel I, the synchro-
nized control culture matured from the ring stage (0 h) to late tropho-
zoites (24 h) to segmenters (36 h). The panel for 24 h shows two
trophozoites in an erythrocyte. Panel II, 5 M FTI-277 exposed cells at
24 and 36 h treatment. Panel III, 10 M FTI-277 exposed cells at 24 and
36 h treatment; panel IV, 5 M GGTI-298 exposed cells at 24 and 36 h
treatment. The panel shows two overlapping trophozoites in an eryth-
rocyte. Panel V, 10 M GGTI-298 exposed cells at 24 and 36 h.
FIG. 7. Inhibition of in vivo radiolabeling of P. falciparum
prenylated proteins with peptidomimetics. Asynchronous cultures
(1 ml) of P. falciparum were labeled with 10 Ci of [3H]farnesol or
[3H]geranylgeraniol for 24 h in the presence or absence of different
concentrations of the FTI-277 (A) or GGTI-298 (B). Labeled parasite
proteins were isolated as described under ”Experimental Procedures“
and resolved by SDS-PAGE. Radiolabeled prenylated proteins were
detected by fluorography.
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(31). We have also shown here that another PFT inhibitor,
FTI-277, blocks maturation of the parasite during the tropho-
zoite stage.
The indirect immunofluorescence experiment provides evi-
dence for the presence of prenylated proteins in all stages of P.
falciparum intraerythrocytic differentiation at distinct subcel-
lular foci. In the segmenter stage, the prenylated proteins show
punctated distribution around chromosomes that are being
organized into individual nuclei. Interestingly, although we
detected insignificant prenylation activity in the ring stage
while labeling with prenol precursor, indirect immunofluores-
cence indicated the presence of prenylated proteins in rings.
This suggests the possibility of a low turnover rate of pre-
existing prenylated proteins. Treatment of ring stage parasites
with both PFT and PGGT inhibitors inhibited prenylation in
trophozoites and schizonts. It is to be noted that at the IC50
concentration of 5 M FTI-277 or GGTI-298 (panels II and IV,
Fig. 6), separation of chromosomes into individual nuclei is
affected and the whole chromosomal structure appears to be in
the form of an unsegregated mass. Therefore, both metabolic
labeling and immunofluorescence studies suggest that proteins
made during the early to late trophozoite stages may be critical
for the trophozoite to schizont transition and the viability of the
parasite.
Earlier studies reported cell-cycle or differentiation depend-
ent protein prenylation in synchronized HepG2 cells (57) and in
the seminiferous epithelium of rats at different stages of sper-
matogenesis (40). The studies in HepG2 cells led the authors to
suggest that protein prenylation could constitute an obligatory
step leading to the duplication of the cellular genome. Several
other studies have now shown that one of the main effects of
prenyltransferase inhibitors is to alter the progression of cell
cycle. PFT inhibitors such as FTI-277 have variable effects on
cell cycle progression, causing either a G0/G1 or G2/M block,
depending on the cell line. On the other hand, PGGT-I inhibi-
tors such as GGTI-298 invariably induce inhibition of G0/G1 (5,
58). Recently, FTI-2153 has been shown to inhibit formation of
bipolar spindle formation and chromosome alignment (59). An-
other PFT inhibitor, SCH66336, inhibits microtubule associa-
tion of farnesylated kinetochore proteins CENP-E (60). Our
results with FTI-277 may represent a situation analogous to
the mammalian cells where bipolar spindle formation is inhib-
ited following PFT inhibitors.
The appearance of distinctive prenylated proteins during
specific stages of P. falciparum differentiation is a novel obser-
vation for parasites. Therefore, it is of considerable interest to
understand the role of prenylated proteins in cell cycle progres-
sion in malaria. Proteins in the 50-kDa range are found pre-
dominately in the trophozoite stage and appear to be of the
same molecular weight but different charge as assessed by
two-dimensional electrophoretic analysis. The migratory differ-
ences could be attributed to differences in phosphorylation or
glycosylation. Phosphorylation seems more likely because
there is little difference in the molecular weights of these
proteins. Earlier studies on protein prenylation in murine lym-
phoma cells (61) and in rat seminiferous epithelium (40) also
described multiple prenylated proteins of the same molecular
weight that appeared to be phosphorylated. Prenylated pro-
teins of different charge and molecular weight were also ob-
served in the 22–28-kDa range from parasites at both the
trophozoite and schizont stages. Although several proteins ap-
pear to be common to the two stages judging from their position
of migration, there is differential labeling with some and at
least one protein is labeled specifically at the schizont stage.
The specificity of PfPFT for the amino acid at the carboxyl
terminus is similar to the mammalian PFT (13, 14, 36) in that
peptides ending in methionine and glutamine are substrates
but is different in that peptides ending in serine, threonine,
and cysteine are not substrates. The specificity of PfPFT is
more similar to that reported for the PFTs of the parasites T.
brucei (28) and Leishmania amazonesis (30), which farnesylate
peptides terminating in methionine and glutamine most effec-
tively and have poor specificity for peptides terminating with
other amino acids. It is difficult, however, to draw firm conclu-
sions about PFT specificity among different species when dif-
ferent short peptides are used in the studies. As noted by
Buckner et al. (28) the specificity of the T. brucei enzyme
changed when a CAAX containing peptide with different amino
acid sequence was used.
It is interesting that PFT and PGGT-I inhibitors are both
effective at inhibiting PfPFT in vitro activity (31) and inhibit-
ing labeling of P. falciparum proteins in culture with farnesol
and geranylgeraniol. This unusual characteristic of PfPFT im-
plies the potential for development of PFT inhibitors with
specificity for the malarial parasite. An in depth analysis of
protein prenylation in P. falciparum will provide us with a
better understanding of the role of these proteins in malarial
cell cycle progression.
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